Life Sciences and Pharma IP Litigation 2025

BRAZIL CONTENTS

4. Patent Term Extensions for Pharmaceutical Products p.31 4.1 Supplementary Protection Certificates p.31 4.2 Paediatric Extensions p.32 4.3 Paediatric-Use Marketing Authorisations p.32 4.4 Orphan Medicines Extensions p.32 5. Relief Available for Patent Infringement p.32 5.1 Preliminary Injunctive Relief p.32 5.2 Final Injunctive Relief p.33 5.3 Discretion to Award Injunctive Relief (Final or Preliminary) p.34 5.4 Damages p.34 5.5 Legal Costs p.36 5.6 Relevance of Claimant/Plaintiff Conduct to Relief p.36 6. Other IP Rights p.36 6.1 Trade Marks p.36 6.2 Copyright p.37 6.3 Trade Secrets p.37 7. Appeal p.37 7.1 Timeframe to Appeal Decision p.37 7.2 Appeal Court(s) Arbiter p.38 7.3 Special Provisions p.38 8. Other Relevant Forums/Procedures p.38 8.1 The UPC or Other Forums p.38 9. Alternative Dispute Resolution p.38 9.1 ADR Options p.38 10. Settlement/Antitrust p.39 10.1 Considerations and Scrutiny p.39 11. Collective Redress p.39 11.1 Group Claims p.39

18

CHAMBERS.COM

Powered by